HARROW, INC. (HROW) Form 8-K — May 11, 2026
Harrow, Inc. reported a first-quarter revenue of $44.2 million, a decrease of 8% year-over-year, primarily due to a non-recurring gross-to-net revenue adjustment for VEVYE, which lowered Q1 revenue by approximately $8 million. Despite this, the company has reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million. VEVYE delivered record new and total prescription performance, with new prescriptions (NRx) up 25% and total prescriptions (TRx) up 11% sequentially.
Key figures
- Eps Beat
- 0
- Revenue
- 44203000
- Guidance
- Second Quarter revenue expected between $71 million and $81 million; Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million.
- Total Debt
- 292087000
- Revenue Yoy
- -8
- Cash Position
- 94644000
- VEVYE revenue
- 20947000
- IHEEZO revenue
- 1851000
- IHEEZO unit demand
- 45,509 units
- Imprimis Rx revenue
- 13499000
- TRIESENCE unit demand
- 10,492 units
- VEVYE prescription growth
- 25% sequentially for NRx and 11% sequentially for TRx
- Other branded products revenue
- 7833000
Price after filing
Close on the filing date to close N calendar days later (from $38.04). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.